Leaps by Bayer
Leverkusen, Germany
Investment Thesis
Leaps by Bayer is Bayer's corporate venture and impact investment arm investing in breakthrough life-science advances addressing ten big challenges in health care and agriculture. The fund takes minority equity stakes primarily from Series A onward, occasionally co-founding companies, and targets transformative innovations in cell and gene therapy, digital health, crop protection, and food and agriculture technology.
Focus Areas
Investment Stage
SeedSeries ASeries B+Growth
Sectors
Investment Signals
GeographyGlobal
RoleBoth
Impact MandateYes
Business Modelsdeep-tech, IP-licensing
Sample Portfolio Companies
Robigo (Series A, led by Leaps)
Celea Therapeutics (USD 180M round, led by Leaps)
Sabanto (Series B, led by Leaps)
EarthOptics (Series C, co-investor)
WellTheory (USD 14M Series A)
Robigo
Celea Therapeutics
Sabanto
EarthOptics
WellTheory
AUM & Sources
N/A
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →Similar Funds
See incorrect information?
Help us keep this directory accurate and up to date.